文献速递血栓与止血

阿加曲班作为心脏手术肝素替代品的快速综述

Use of argatroban as a heparin alternative in cardiac surgery-a rapid review of case reports and series.
PubMed 文献 · J Thromb Haemost · 2026-06-17

结果显示初始推注中位剂量0.1 mg/kg,中位输注速率6.8 μg/kg/min,ACT反应非线性且70%病例波动>100秒,尽管ACT≥400秒仍有40%发生回路血栓,80%需围术期输血。结论认为阿加曲班作为CPB肝素替代品存在不可预测的ACT反应和频繁回路血栓等重大局限。

要点

  • 阿加曲班用于CPB时ACT反应非线性,70%病例波动>100秒。
  • 尽管ACT≥400秒,回路血栓发生率仍达40%,多见于储血器或氧合器。
  • 停药后ACT恢复至<200秒中位需7小时,80%病例需围术期输血。

核心结论

  • 已发表经验显示阿加曲班作为CPB肝素替代品存在不可预测的ACT反应和频繁回路血栓等重大局限。
  • 并发症发生率应视为上限,因病例级证据的描述性本质和发表偏倚可能性。

研究设计与样本

  • 快速综述遵循PRISMA和Cochrane Rapid Reviews指南,检索MEDLINE、Embase等数据库。

主要发现

  • 初始阿加曲班推注中位剂量0.1 mg/kg,为达到ACT≥400秒而加倍。
  • 中位输注速率(25th-75th百分位)为6.8(4.6-9.7)μg/kg/min。
  • ACT反应非线性,70%病例出现>100秒的波动。
  • 尽管ACT≥400秒,回路血栓发生于40%病例,最常见于储血器或氧合器。
  • 停药后ACT恢复至<200秒中位需7小时,围术期输血发生于80%病例。

临床怎么用

  • 阿加曲班用于CPB抗凝时需注意ACT反应不可预测,应加强监测。
  • 即使ACT≥400秒仍应警惕回路血栓风险,特别是储血器和氧合器。
  • 停药后ACT恢复较慢,需考虑围术期输血需求。

局限性

  • 证据基于病例报告和系列,为描述性证据,并发症发生率可能受发表偏倚影响而偏高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Argatroban has been used as an alternative anticoagulant for cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia (HIT) or heparin allergy. Its mechanism of action differs from heparin, and concerns regarding dosing, monitoring, and circuit thrombosis risk remain insufficiently characterized. OBJECTIVES: This study systematically reviewed published cases of argatroban anticoagulation during CPB for dosing patterns, activated clotting time (ACT) responses, thrombotic and bleeding events, and transfusions. METHODS: A rapid review was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Rapid Reviews guidance. Searches of MEDLINE, Embase, and other index databases identified clinical reports involving argatroban use during CPB. Two investigators independently screened studies, extracted data, and assessed risk of bias. RESULTS: Twenty-nine publications describing 30 patients (24 adult and 6 pediatric cases) met inclusion criteria. The median initial argatroban bolus was 0.1 mg/kg, but it was doubled to achieve ACTs of ≥400 seconds. Median infusion rate (25th-75th percentile) was 6.8 (4.6-9.7) μg/kg/min. ACT responses were nonlinear, with fluctuations of >100 seconds occurring in 70% of cases. Despite ACTs of ≥400 seconds, circuit thrombosis occurred in 40% of cases, most commonly in the reservoir or oxygenator. Recovery to ACT of <200 seconds required a median of 7 hours after discontinuing drug infusion. Perioperative transfusion occurred in 80% of cases. CONCLUSION: Published experience demonstrates major limitations of argatroban as a heparin substitute for CPB, including unpredictable ACT responses and frequently documented circuit thromboses. The reported complication rates should be interpreted as an upper bound given the descriptive nature of case-level evidence and the likelihood of publication bias.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bouvette S, Butt AL, Clifton SC, et al. Use of argatroban as a heparin alternative in cardiac surgery-a rapid review of case reports and series. J Thromb Haemost. 2026. PMID: 42303156. doi:10.1016/j.jtha.2026.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。